Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients

COLEMAN is an opened prospective monocentric non-randomized study, initiated by the Hospices Civils de Lyon. Population targeted are patients from 18 years old with stage III or IV metastatic melanoma eligible for a metastatic melanoma treatment administered as part of usual care. The objective is to study the variations of immune infiltrate and cell plasticity before and under immunotherapy or targeted therapy. Two biopsies are done before and one month after the treatment initiation and one blood sample is done after the treatment initiation. 100 patients will be included and followed duri

Trial Details

NCT ID
NCT05029791
Phase
NA
Sponsor
Hospices Civils de Lyon
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Tumor biopsy
  • Blood sample
Locations (sample)
  • Lyon, France

Key Eligibility Criteria

  • Patient age ≥ 18
  • Female patients must agree to the use of 2 methods of contraception. For man one method of contraception is needed if if his partner is in childbea…
  • Patients with metastatic stage III or IV melanoma relapse
  • Eligible for a melanoma metastatic treatment indicated and administered as part of usual care

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →